Merck and Eisai Phase 3 Miss Shakes Up Kidney Cancer Race – Analysts Split on Arcus
Merck’s new kidney cancer combos failed in Phase 3, missing key goals; analysts see mixed impact for Arcus and its drug.
/ 9 items
#RCUS↓
Arcus Biosciences Stops Phase 3 STAR-121 Lung Cancer Trial and Updates Gilead Partnership
Arcus stops a lung cancer trial early after poor outlook, ends a partner study, and gains more control as Gilead scales back the deal.
Wedbush Upgrades Arcus Biosciences Ahead of Key 2026 Clinical Data
Wedbush upgraded Arcus Biosciences with a new $41 price target and added the stock to its Best Ideas List ahead of major 2026 clinical updates for casdatifan in kidney cancer.
Damora Therapeutics Taps Biotech Veteran Jennifer Jarrett as President and CEO
Damora has appointed biotech leader Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Two industry veterans also join the Board of Directors.
Goldman Sachs Upgrades Arcus Biosciences to Buy on Strong Cancer Drug Data
Goldman Sachs upgraded Arcus Biosciences to Buy, raising its price target to $28 on promising results for its lead cancer drug Casdatifan.
Morgan Stanley Changes Ratings on RCUS, NRIX, IOBT
Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects.